抗体を用いない癌ワクチンの競合動向

Abstract

Introduction

New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last three years the cancer vaccine industry has reshaped itself quite considerably. The number of cancer vaccine players has rather decreased than increased, through operational re-prioritizations, M&As and fall outs.

Scope of this report

• In-depth competitive landscape assessment of the cancer vaccine market
• Tumor antigen discovery and technologies surrounding it
• Thorough review of immunomodulating strategies and adjuvants
• Thorough review of cancer vaccine delivery and technologies surrounding it
• Progress analysis of six major cancer vaccine indications, including players, drugs, clinical progress and pitfalls

Research and analysis highlights

Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline's acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications.

Table of Contents

1 Executive Summary

2 Cancer Highlights

3 Methodology

• 4 Table of Contents
• 4.1 List of Boxes
• 4.2 List of Figures
• 4.3 List of Tables

5 Vaccine Strategies: Challenges & Opportunities

6 Competitive Landscape in Cancer Vaccines

• 6.1 Countries & Players: Who are In the Lead?
  • 6.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
  • 6.1.2 Approved Cancer Vaccine Drugs: Performance
• 6.2 Deals & Alliances in Cancer Vaccines
  • 6.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
  • 6.2.2 Deals in Prostate Cancer
  • 6.2.3 Deals in Breast Cancer
  • 6.2.4 Deals in Leukemia & Lymphoma
  • 6.2.5 Drug Delivery Deals in Cancer Vaccines
  • 6.2.6 Adjuvant Deals

7 Tumor Antigens

• 7.1 Tumor Antigens: General Comments
• 7.2 Antigen Discovery
  • 7.2.1 Classical Immunology Approach
  • 7.2.2 The Reverse Immunology Approach
  • 7.2.3 Company Platforms
    • 7.2.3.1 Epitope Identification System - EIS®
    • 7.2.3.2 EPIQUEST system
    • 7.2.3.3 MolecularBreeding™ & MaxyScan™
    • 7.2.3.4 ProtEx™ technology
    • 7.2.3.5 Rapid Identification of Alternative Splicing (RIAS) System
    • 7.2.3.6 SMARTOMICS™
• 7.3 Specific Antigen Processing Technologies Increasing Antigen Presentation

8 Immunomodulators & Adjuvants in Cancer Vaccines

• 8.1 Overview
• 8.2 Cytokines
  • 8.2.1 Vaccines in Combination with Interleukin-2
  • 8.2.2 Tumor Necrosis Factor
  • 8.2.3 Interferons
• 8.3 Adjuvants
• 8.4 Other Immunomodulating Strategies
  • 8.4.1 An Immune Response Modifying Protein
  • 8.4.2 Immunostimulatory DNA
  • 8.4.3 Ex Vivo Stimulated Immune Cells
  • 8.4.4 Fusion Protein Gain Potent Immune Response
  • 8.4.5 Macrophage and Natural Killer Cells Activation
  • 8.4.6 Selective Suppression of the Immune System to An Antigen
  • 8.4.7 TAP Technology

9 Cancer Vaccine Delivery

• 9.1 Viral Delivery
  • 9.1.1 Introduction
  • 9.1.2 Viral Constructs Put into Use
    • 9.1.2.1 Replicon-based RNA and DNA vaccines
      • 9.1.2.1.1 The Alphavaccine Platform System - ArV™
      • 9.1.2.1.2 MVA-BN
    • 9.1.2.2 Retroviruses
      • 9.1.2.2.1 The SDSV-platform
    • 9.1.2.3 Lentivirus
      • 9.1.2.3.1 LentiPak™
      • 9.1.2.3.2 LentiVector™⁄ pEGASUS™
    • 9.1.2.4 Adenoviruses
      • 9.1.2.4.1 Failed Adenovirus Delivery Platforms
      • 9.1.2.4.2 GVAX
      • 9.1.2.4.3 TNFerade™
      • 9.1.2.4.4 INGN-225
    • 9.1.2.5 Adeno-associated viruses
      • 9.1.2.5.1 Failed AAV Delivery Platforms
      • 9.1.2.5.2 Genzyme Acquires AAV vector Technology
      • 9.1.2.5.3 MediGene's AAV Platform
    • 9.1.2.6 Herpes Simplex Viruses
      • 9.1.2.6.1 DISC-HSV
      • 9.1.2.6.2 ImmunoVEX
    • 9.1.2.7 Poxviruses
      • 9.1.2.7.1 Hi-8™ PrimeBoost™ platform
      • 9.1.2.7.2 PROSTVAC-VF
      • 9.1.2.7.3 Transgene's MVA Platform
      • 9.1.2.7.4 TroVax
    • 9.1.2.8 Other Poxvirus Systems
    • 9.1.2.9 Baculovirus
    • 9.1.2.9.1 Chimeric virus -like particles (CVLPs)
• 9.2 Bacterias
• 9.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
  • 9.3.1 Introduction
  • 9.3.2 Cell Therapy Strategies
    • 9.3.2.1 Processed Tumor Cells
    • 9.3.2.2 Lysed Tumor Cell Line
    • 9.3.2.3 The Dendritic Cell Strategy that Didn't Work Out
    • 9.3.2.4 HSPs
    • 9.3.2.5 Provenge™
    • 9.3.2.6 Dendritophages
    • 9.3.2.7 Cell-targeting Antibodies
    • 9.3.2.8 Increase Dendritic Cell Number
    • 9.3.2.9 DCVax®
    • 9.3.2.10 ACTIVATE™
• 9.4 Synthetic Delivery Systems & Strategies
  • 9.4.1 Introduction
  • 9.4.2 Biotransport™
  • 9.4.3 Biotype®vector
  • 9.4.4 DNAVax Gene Delivery System
  • 9.4.5 FusitAb™
  • 9.4.6 GeneDrug™
  • 9.4.7 Molecular Conjugates
  • 9.4.8 Naked DNA Delivery
  • 9.4.9 PVLP Technology
  • 9.4.10 Sphingosomal Drug Delivery Technology
  • 9.4.11 STEALTH
  • 9.4.12 Failed Liposomal Systems

10 Non-Antibody Based Vaccines in Development: By Major Indications

• 10.1 General Oncology Overview
• 10.2 Progress Analysis - Melanoma
• 10.3 Progress Analysis - Breast Cancer
• 10.4 Progress Analysis - Prostate Cancer
• 10.5 Progress Analysis - Lung Cancer
• 10.6 Progress Analysis - Colorectal Cancer
• 10.7 Progress Analysis - Cervical Cancer

11 Disclaimer

• 11.1 Liability
• 11.2 Completeness

12 Drug Index

13 Company Index